Epilepsy Market Size Analysis and Forecast 2030

Epilepsy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Publication Month : Feb 2024

  • Report Code : TIPRE00016405
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 230
Inquire Before Buy

PRICING

$5190

$4152

[Research Report] The epilepsy market size is projected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is estimated to record a CAGR of 4.1% during 2022–2030.

Market Insights and Analyst View:

Epilepsy is a chronic disease of the brain that results in disturbed nerve cell activity, causing seizures. It is characterized by recurrent seizures involving either a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may develop as a genetic disorder or through an acquired brain injury, such as a trauma or stroke. The consumer demand for treatments is set to increase due to the heightened vulnerability of elderly patients suffering from epilepsy, who are at a greater risk of the condition.

The factors driving the growth of the epilepsy market include the rising prevalence of epilepsy and growing investments in the development of epilepsy therapies. Moreover, in recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Further, the development of gene therapy as a promising treatment approach is likely to bring significant epilepsy market trends in the coming years.

Growth Drivers:

Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. The condition may occur due to a genetic disorder or an acquired brain injury, such as a trauma or stroke. It is characterized by recurrent seizures, which are short episodes of involuntary movement of a body part or the entire body. Seizures can modify sensations, behaviors, muscle movements, and awareness. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4–10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries and the elevated risk of endemic conditions such as neurocysticercosis or malaria.

The WHO states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives the epilepsy market growth during the forecast period.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Epilepsy Market: Strategic Insights

epilepsy-market
Market Size Value inUS$ 7.7 billion in 2022
Market Size Value byUS$ 10.7 billion by 2030
Growth rateCAGR of 4.1% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The epilepsy market analysis has been carried out by considering the following segments: type, route of administration, treatment type, age group, distribution channel, and geography. Based on type, the market is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In terms of route of administration, the market is classified into oral, parenteral, and others. The market, by treatment type, is segmented into first-generation drugs, second-generation drugs, and third-generation drugs. In terms of age group, the market is bifurcated into adults and children.

Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. The geographic scope of the epilepsy market report covers North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The epilepsy market, by type, is segmented into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In 2022, the generalized epilepsy segment held the largest share of the market. It is expected to register the highest CAGR in the market during 2022–2030. Generalized epilepsy involves widespread electrical disruptions in the brain from the outset. The condition can frequently impact both sides of the body, causing the loss of consciousness. Seizures that arise from both sides of the brain at the same time are characteristic of generalized epilepsy. The goal of therapeutics for generalized epilepsy is to regulate and prevent the brain's excessive electrical activity. These therapeutics may contain medications that target both the cortex and deep brain areas. AEDs are widely adopted for this epilepsy, thereby addressing diverse indications.

Epilepsy Market, by Type – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Based on the route of administration, the epilepsy market is segmented into oral, parenteral, and others. In 2022, the oral segment held the largest share of the market. The market for this segment is expected to grow at the highest CAGR during 2022–2030. Oral administration is a prominent route of AED administration, especially among patients with chronic epilepsy. Oral AEDs primarily include immediate-release and modified-release (delayed-release and extended-release) dosage formulations. Oral medications confer the ease of use, allowing patients to self-administer and adhere to prescribed regimens. This route is favored for its simplicity compared to other administration routes, such as intramuscular and intravenous injections.

Based on treatment type, the epilepsy market is categorized into first-generation drugs, second-generation drugs, and third-generation drugs. The third-generation drugs segment held the largest epilepsy market share in 2022. The segment is estimated to register the highest CAGR during 2022–2030. Third-generation AEDs, identified as advanced or next-generation AEDs, mainly include eslicarbazepine acetate, lacosamide, and cannabidiol. The drugs are claimed to be superior to the first- and second-generation AEDs in terms of safety and efficacy. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes (Lennox–Gastaut syndrome and Dravet syndrome) and tuberous sclerosis. Most of the third-generation AEDs exhibit fewer adverse effects, resulting in increased patient treatment adherence. These drugs are also effective, safe, and generally well-tolerated in children. Third-generation drugs are gaining importance but are not prescribed as frequently as second-generation anti-epileptic drugs.

Based on age group, the epilepsy market is segmented into adults and children. In 2022, the adult segment held a larger share of the market. It is further expected to register a higher CAGR in the market during 2022–2030. Epilepsy is more likely to develop in adults as some risk factors for this disease are more common in adults; these include diseases affecting brain function (such as Alzheimer’s disease), brain tumors, strokes, and head injuries. According to the Centers for Disease Control and Prevention (CDC), 3 million adults aged 18 or older are living with active epilepsy in the US. Nearly 1 million of these adults are aged 55 or older. As the population ages, even more older people are likely to suffer from epilepsy in the coming years. In 2021, 1.1% of US adults (~2.86 million adults) reported active epilepsy. Thus, medications and treatment strategies often prioritize adult patients, aligning with the demographic prevalence of epilepsy in this age group.

Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. In addition, the retail pharmacies segment is expected to register the highest CAGR in the market during 2022–2030.

Regional Analysis:

The geographic scope of the epilepsy market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. The market growth in North America is attributed to a rise in the number of people affected by epilepsy, a growing aging population, ongoing R&D in the field of epilepsy therapeutics, regulatory approvals for new products, and a rise in the number of accidents and brain injuries. In 2022, the US held the largest share of the market in the region.

According to the CDC, nearly 1.2% of individuals in the US have active epilepsy. The condition affects 3 million adults and 470,000 children in the country. The burgeoning number of cases of neurological diseases such as Alzheimer's disease, increasing awareness about neurological disorders, favorable results obtained in research activities, and growing investments in epilepsy drug development are among the main factors driving the overall epilepsy market growth in the US.

In March 2020, Neurelis, Inc. announced the commercial availability of VALTOCO (diazepam nasal spray) to treat stereotypic, intermittent episodes of frequent seizures (i.e., acute repetitive seizures and seizure clusters) that are different from a usual seizure pattern observed in pediatric and adult patients. Similarly, in March 2022, the FDA approved Ztalmy (ganaxolone) to treat seizures related to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2 and older.

In August 2021, the CDC Epilepsy Program selected the Epilepsy Foundation as its funding recipient under a new cooperative agreement: Improving Systems of Care, Epilepsy Education, and Health Outcomes through National and Community Partnerships. The US$ 17.5 million in federal funds that would be allotted over the next 5 years would support the work of the Epilepsy Foundation and its partners in creating and maintaining a robust public health infrastructure, advancing health equity, improving quality of life, and achieving the best outcomes for all people living with the epilepsies. Therefore, the increasing prevalence of epilepsy, new drug launches, and research and funding initiatives bolster the growth of the epilepsy market in the US.

Industry Developments and Future Opportunities:

Initiatives taken by market players operating in the global epilepsy market are listed below:

  • In January 2024, Eisai Co Ltd received approval from the Japanese Ministry of Health, Labour, and Welfare for the sale of Fycompa (perampanel) injection formulations in the country. The product is approved as an alternative therapy when oral administration is temporarily impossible. For instance, the oral administration of the drugs may result in the risk of seizures during surgery. As a result, the company has developed an injection formulation of Fycompa to offer a new form of the drug, alongside the tablet and fine granule formulations that are already available in Japan.
  • In May 2023, Neuro3 Therapeutics (Neuro3), which focuses on finding and creating novel medications to treat illnesses of the central nervous system, signed an exclusive global license and option deal with Lundbeck (Denmark). The agreement focuses on KCNQ2 ion channel activators, which have been clinically verified as targets for epilepsy treatment.

Competitive Landscape and Key Companies:

The epilepsy market forecast can help stakeholders plan their growth strategies. Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS are among the prominent players in the market. The market players focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment is dominating the epilepsy market?

The global epilepsy market is segmented based on type, route of administration, treatment type, age group, distribution channel. The epilepsy market, by type, is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In 2022, the generalized epilepsy segment held the largest share of the market. It is expected to register the highest CAGR in the market during 2022–2030.

What was the estimated epilepsy market size in 2022?

The epilepsy market was valued at US$ 7.7 billion in 2022.

What are the growth estimates for the epilepsy market till 2030?

The epilepsy market is expected to be valued at US$ 10.7 billion in 2030.

Who are the major players in the epilepsy market?

The epilepsy market majorly consists of the players, including Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS.

What is the driving and restraining factors for the epilepsy market?

The factors driving the growth of the epilepsy market include the rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies. However, the recall of products hampers the growth of the epilepsy market.

What is epilepsy?

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

The List of Companies - Epilepsy Market

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. CombiGene AB
  6. Livanova PLC
  7. Novartis AG
  8. Medtronic PLC
  9. GSK PLC
  10. H. Lundbeck AS.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Epilepsy Market